The company, founded in 2020 and based in Cambridge, Massachusetts, creates innovative cell-based medicines for cancer and other diseases by combining stem cell biology, immunology, regenerative medicine, and gene editing. They offer human pluripotent stem cells and their adult derivatives to clients and are well-funded.